August 23, 2010
Taro Provides Preliminary First Half 2010 Financial Results
More 
August 04, 2010
Taro Files Audited Financials for the Year Ended December 31, 2007
More
June 14, 2010
Taro Provides Preliminary First Quarter 2010 Financial Results
More
June 14, 2010
Taro Provides Preliminary First Quarter 2010 Financial Results
More
June 14, 2010
Taro Provides Preliminary First Quarter 2010 Financial Results
More
June 03, 2010
Taro Receives FDA Approval for Granisetron Hydrochloride Tablets
More
June 03, 2010
Taro Receives FDA Approval for Granisetron Hydrochloride Tablets
More
June 03, 2010
Taro Receives FDA Approval for Granisetron Hydrochloride Tablets
More
June 03, 2010
Taro Receives FDA Approval for Granisetron Hydrochloride Tablets
More
April 30, 2010
Taro Provides Preliminary 2009 Full Year Results
More
April 30, 2010
Taro Provides Preliminary 2009 Full Year Results
More
April 30, 2010
Taro Provides Preliminary 2009 Full Year Results
More
April 30, 2010
Taro Provides Preliminary 2009 Full Year Results
More
April 06, 2010
Taro Receives Patent for T2007, the Company's Second Proprietary Non-Sedating Barbiturate Drug
More
April 06, 2010
Taro Receives Patent for T2007, the Company's Second Proprietary Non-Sedating Barbiturate Drug
More
April 06, 2010
Taro Receives Patent for T2007, the Company's Second Proprietary Non-Sedating Barbiturate Drug
More
April 06, 2010
Taro Receives Patent for T2007, the Company's Second Proprietary Non-Sedating Barbiturate Drug
More
March 25, 2010
Taro Files Audited Financials for the Year Ended December 31, 2006 and Restated Financials for 2005 and 2004
More
March 25, 2010
Taro Files Audited Financials for the Year Ended December 31, 2006 and Restated Financials for 2005 and 2004
More
March 25, 2010
Taro Files Audited Financials for the Year Ended December 31, 2006 and Restated Financials for 2005 and 2004
More
March 25, 2010
Taro Files Audited Financials for the Year Ended December 31, 2006 and Restated Financials for 2005 and 2004
More
March 8, 2010
Taro Receives FDA Approval for Fluorouracil Topical Cream USP, 5%
More
March 8, 2010
Taro Receives FDA Approval for Fluorouracil Topical Cream USP, 5%
More
March 8, 2010
Taro Receives FDA Approval for Fluorouracil Topical Cream USP, 5%
More
March 8, 2010
Taro Receives FDA Approval for Fluorouracil Topical Cream USP, 5%
More
February 18, 2010
Taro Announces Planned Discontinuation of Manufacturing Operations at Its Irish Facility
More
February 18, 2010
Taro Announces Planned Discontinuation of Manufacturing Operations at Its Irish Facility
More
February 18, 2010
Taro Announces Planned Discontinuation of Manufacturing Operations at Its Irish Facility
More
February 18, 2010
Taro Announces Planned Discontinuation of Manufacturing Operations at Its Irish Facility
More
February 4, 2010
Israel Supreme Court Prohibits Sun From Exercising Warrant While Temporary Junction In Affect
More
February 4, 2010
Israel Supreme Court Prohibits Sun From Exercising Warrant While Temporary Junction In Affect
More
February 4, 2010
Israel Supreme Court Prohibits Sun From Exercising Warrant While Temporary Junction In Affect
More
February 4, 2010
Israel Supreme Court Prohibits Sun From Exercising Warrant While Temporary Junction In Affect
More
February 2, 2010
Taro Receives FDA Approval For Levetiracetam Tablets
More
February 2, 2010
Taro Receives FDA Approval For Levetiracetam Tablets
More
February 2, 2010
Taro Receives FDA Approval For Levetiracetam Tablets
More
February 2, 2010
Taro Receives FDA Approval For Levetiracetam Tablets
More
December 31, 2009
Taro Reports Voting Results from Its Annual General Meeting
More
December 31, 2009
Taro Reports Voting Results from Its Annual General Meeting
More
December 10, 2009
Taro Sends Important Update to Shareholders
More
December 10, 2009
Taro Sends Important Update to Shareholders
More
December 08, 2009
Taro Sends Letter to Update Shareholders
More
December 08, 2009
Taro Sends Letter to Update Shareholders
More
December 04, 2009
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taro's Proprietary Non-Sedating Barbiturate Compound
More
December 04, 2009
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taro's Proprietary Non-Sedating Barbiturate Compound
More
December 02, 2009
Taro Provides Perliminary Third Quarter and Year-to-Date 2009 Financial Results.
More
December 02, 2009
Taro Provides Perliminary Third Quarter and Year-to-Date 2009 Financial Results.
More
September 29, 2009
Taro Files Lawsuit Against Sun in U.S. Federal Court
More
September 29, 2009
Taro Files Lawsuit Against Sun in U.S. Federal Court
More
September 11, 2009
Taro Announces Postponement of September 13, 2009 Shareholders Meeting
More
September 11, 2009
Taro Announces Postponement of September 13, 2009 Shareholders Meeting
More
July 27, 2009
Taro Receives FDA Approval for Cetirizine Hydrochloride Tablets (OTC) ANDA
More
July 27, 2009
Taro Receives FDA Approval for Cetirizine Hydrochloride Tablets (OTC) ANDA
More
July 27, 2009
Taro Sues Synerx Pharma, Karalex Pharma and DPT Laboratories for Patent Infringement
More
July 27, 2009
Taro Sues Synerx Pharma, Karalex Pharma and DPT Laboratories for Patent Infringement
More
July 15, 2009
Taro Receives Patent for Ovide(R)
More
July 15, 2009
Taro Receives Patent for Ovide(R)
More
June 11, 2009
Taro Announces Preliminary Court Approval of Settlement in Securities Lawsuit
More
June 11, 2009
Taro Announces Preliminary Court Approval of Settlement in Securities Lawsuit
More
June 10, 2009
Taro and Quinnova Announce Agreement to Co-Promote "Neosalus" and "Cleanse & Treat" in the United States
More
June 10, 2009
Taro and Quinnova Announce Agreement to Co-Promote "Neosalus" and "Cleanse & Treat" in the United States
More
May 22, 2009
Taro to Restate Financial Results for 2004 and 2005; Revises 2006, 2007 and 2008 Estimated Financial Results
More
May 22, 2009
Taro to Restate Financial Results for 2004 and 2005; Revises 2006, 2007 and 2008 Estimated Financial Results
More
May 22, 2009
Taro Provides Preliminary First Quarter 2009 Financial Results
More
May 22, 2009
Taro Provides Preliminary First Quarter 2009 Financial Results
More
April 03, 2009
Taro Receives Final FDA Approval for Carbamazepine Extended-Release Tablets
Generic Equivalent to Novartis' Tegretol(r)-XR Tablets USP, 100 mg, 200 mg and 400 mg
HAWTHORNE, N.Y., Apr 3, 2009 (GlobeNewswire via COMTEX) -- Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company") (Pink Sheets:TAROF) today reported that it received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application ("ANDA") for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg and 400 mg ("carbamazepine extended-release tablets").
More
April 03, 2009
Taro Receives Final FDA Approval for Carbamazepine Extended-Release Tablets
Generic Equivalent to Novartis' Tegretol(r)-XR Tablets USP, 100 mg, 200 mg and 400 mg
HAWTHORNE, N.Y., Apr 3, 2009 (GlobeNewswire via COMTEX) -- Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company") (Pink Sheets:TAROF) today reported that it received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application ("ANDA") for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg and 400 mg ("carbamazepine extended-release tablets").
More
February 11, 2009
Taro Receives FDA Approval for Levetiracetam Oral Solution
Generic Equivalent to UCB's Keppra(r) Oral Solution, 100 mg/mL
HAWTHORNE, N.Y., Feb. 11, 2009 (GlobeNewswire via COMTEX) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company") (Pink Sheets:TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Levetiracetam Oral Solution, 100 mg/mL ("levetiracetam oral solution").
More
February 11, 2009
Taro Receives FDA Approval for Levetiracetam Oral Solution
Generic Equivalent to UCB's Keppra(r) Oral Solution, 100 mg/mL
HAWTHORNE, N.Y., Feb. 11, 2009 (GlobeNewswire via COMTEX) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company") (Pink Sheets:TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Levetiracetam Oral Solution, 100 mg/mL ("levetiracetam oral solution").
More
February 06, 2009
TARO RECEIVES FDA WARNING LETTER FOLLOWING INSPECTION OF ITS CANADIAN MANUFACTURING FACILITY
The Company has Already Taken Corrective Action Regarding Many of the Comments Contained in the Letter
HAWTHORNE, N.Y., Feb. 6, 2009 - Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) announced that yesterday, February 5, 2009, it received a warning letter from the U.S. Food and Drug Administration (“FDA”) regarding the inspection of the Company’s Canadian manufacturing facility in July 2008. This is the first such letter that the Company or any of its affiliates has ever received.
More
February 06, 2009
TARO RECEIVES FDA WARNING LETTER FOLLOWING INSPECTION OF ITS CANADIAN MANUFACTURING FACILITY
The Company has Already Taken Corrective Action Regarding Many of the Comments Contained in the Letter
HAWTHORNE, N.Y., Feb. 6, 2009 - Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) announced that yesterday, February 5, 2009, it received a warning letter from the U.S. Food and Drug Administration (“FDA”) regarding the inspection of the Company’s Canadian manufacturing facility in July 2008. This is the first such letter that the Company or any of its affiliates has ever received.
More
February 05, 2009
Taro Receives Final FDA Approval for Lamotrigine Chewable Tablets ANDA
Generic Equivalent to GlaxoSmithKline's Lamictal(r) CD Tablets, 5 mg and 25 mg
HAWTHORNE, N.Y., Feb. 5, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Lamotrigine Tablets (Chewable Dispersible), 5 mg and 25 mg ("lamotrigine chewable tablets").
More
February 05, 2009
Taro Receives Final FDA Approval for Lamotrigine Chewable Tablets ANDA
Generic Equivalent to GlaxoSmithKline's Lamictal(r) CD Tablets, 5 mg and 25 mg
HAWTHORNE, N.Y., Feb. 5, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Lamotrigine Tablets (Chewable Dispersible), 5 mg and 25 mg ("lamotrigine chewable tablets").
More
February 02, 2009
Taro Provides Preliminary 2008 Full Year Results
Net Income in 2008 Increases 143% to $51 Million From $21 Million in 2007 $74 Million Net Cash Generated From Operations in 2008
HAWTHORNE, N.Y., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) today provided preliminary, unaudited and unreviewed information on its financial performance for the year ended December 31, 2008.
More
February 02, 2009
Taro Provides Preliminary 2008 Full Year Results
Net Income in 2008 Increases 143% to $51 Million From $21 Million in 2007 $74 Million Net Cash Generated From Operations in 2008
HAWTHORNE, N.Y., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) today provided preliminary, unaudited and unreviewed information on its financial performance for the year ended December 31, 2008.
More
January 28, 2009
Taro Receives Final FDA Approval for Lamotrigine Tablets ANDA
Generic Equivalent to GlaxoSmithKline's Lamictal(r) Tablets, 25 mg, 100 mg, 150 mg and 200 mg
HAWTHORNE, N.Y., Jan. 28, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Lamotrigine Tablets 25 mg, 100 mg, 150 mg, and 200 mg ("Lamotrigine Tablets"). Taro had received tentative approval for this ANDA in March 2008.
More
January 28, 2009
Taro Receives Final FDA Approval for Lamotrigine Tablets ANDA
Generic Equivalent to GlaxoSmithKline's Lamictal(r) Tablets, 25 mg, 100 mg, 150 mg and 200 mg
HAWTHORNE, N.Y., Jan. 28, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Lamotrigine Tablets 25 mg, 100 mg, 150 mg, and 200 mg ("Lamotrigine Tablets"). Taro had received tentative approval for this ANDA in March 2008.
More
January 06, 2009
Sun Refuses to Accept Taro's Offer to Mediate
More
January 06, 2009
Sun Refuses to Accept Taro's Offer to Mediate
More